Cellular expression profiles of Epstein-Barr virus-transformed B-lymphoblastoid cell lines.

B cells B-lymphoblastoid cell lines Epstein-Barr virus gene expression microarray

Journal

Biomedical reports
ISSN: 2049-9434
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 08 04 2020
accepted: 03 08 2020
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 17 9 2020
Statut: ppublish

Résumé

Epstein-Barr virus (EBV) can infect human B cells and is associated with various types of B cell lymphomas. Studies on the global alterations of the cellular pathways mediated by EBV-induced B cell transformation are limited. In the present study, microarray analysis was performed following generation of two EBV-infected B-lymphoblastoid cell lines (BLCL), in which normal B cells obtained from two healthy Thai individuals and transcriptomic profiles were compared with their respective normal B cells. The two EBV-transformed BLCL datasets exhibited a high degree of similarity between their RNA expression profiles, whereas the two normal B-cell datasets did not exhibit the same degree of similarity in their RNA expression profiles. Differential gene expression analysis was performed, and the results showed that EBV infection was able to dysregulate several cellular pathways in the human B-cell genes involved in cancer and cell activation, such as the MAPK, WNT and PI3K-Akt signaling pathways, which were upregulated in the BLCL and were associated with increased cellular proliferation and immortalization of EBV-infected B cells. Expression of proteins located in the plasma membrane, which initiate a biological response to ligand binding, were also notably upregulated. Expression of genes involved in cell cycle control, the p53 signaling pathway and cellular senescence were downregulated. In conclusion, genes that were markedly upregulated by EBV included those involved in the acquisition of a tumorigenic phenotype of BLCL, which was positively correlated with several hallmarks of cancer.

Identifiants

pubmed: 32934816
doi: 10.3892/br.2020.1350
pii: BR-0-0-01350
pmc: PMC7469576
doi:

Types de publication

Journal Article

Langues

eng

Pagination

43

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright: © Chaiwongkot et al.

Références

Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):16046-16055
pubmed: 31341086
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Cell Prolif. 2007 Apr;40(2):268-81
pubmed: 17472732
Int J Mol Cell Med. 2012 Spring;1(2):75-87
pubmed: 24551762
Front Microbiol. 2016 Oct 25;7:1602
pubmed: 27826287
Oncogenesis. 2015 Oct 19;4:e171
pubmed: 26479443
Turk J Biol. 2020 Feb 17;44(1):1-14
pubmed: 32123491
Int J Cell Biol. 2012;2012:594681
pubmed: 22500174
J Cell Sci. 2011 Apr 15;124(Pt 8):1183-93
pubmed: 21444749
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6
pubmed: 14663138
Oncol Rep. 2015 May;33(5):2253-60
pubmed: 25760809
Adv Exp Med Biol. 2017;1018:57-74
pubmed: 29052132
J Virol. 2019 Jun 14;93(13):
pubmed: 31019051
Cancer Sci. 2014 May;105(5):537-44
pubmed: 24581222
J Infect Dis. 2013 Oct 15;208(8):1286-93
pubmed: 23868878
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
PeerJ. 2017 Mar 14;5:e3089
pubmed: 28316892
J Med Virol. 2019 Mar;91(3):444-449
pubmed: 30229949
Cells. 2019 Apr 06;8(4):
pubmed: 30959874
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16242-3
pubmed: 25385596
Oncotarget. 2017 Jul 22;8(38):63738-63749
pubmed: 28969025
Clin Infect Dis. 2014 Aug 15;59(4):501-8
pubmed: 24820696
J Vis Exp. 2011 Nov 08;(57):
pubmed: 22090023
Oncogene. 2016 Jun 30;35(26):3419-31
pubmed: 26568302
Pharmacogenet Genomics. 2019 Apr;29(3):58-64
pubmed: 30562215
Cancers (Basel). 2019 Jul 23;11(7):
pubmed: 31340499
Sci Rep. 2018 May 22;8(1):8010
pubmed: 29789630
J Virol. 2019 Jun 14;93(13):
pubmed: 30971472
Biomed Rep. 2018 Jul;9(1):42-52
pubmed: 29930804
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20464-9
pubmed: 19920174
J Virol. 2002 Oct;76(20):10427-36
pubmed: 12239319
Oncotarget. 2018 Jan 2;9(12):10417-10435
pubmed: 29535816
Microbes Infect. 2010 Mar;12(3):173-81
pubmed: 20004735
PLoS One. 2018 Aug 22;13(8):e0202537
pubmed: 30133498
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Front Oncol. 2018 Aug 02;8:265
pubmed: 30116721
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238

Auteurs

Arkom Chaiwongkot (A)

Applied Medical Virology Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Nakarin Kitkumthorn (N)

Department of Oral Biology, Faculty of Dentistry, Mahidol University, Bangkok 10400, Thailand.

Ratakorn Srisuttee (R)

Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok 10520, Thailand.

Supranee Buranapraditkun (S)

Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center-Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Classifications MeSH